Market Cap 272.57M
Revenue (ttm) 0.00
Net Income (ttm) -19.36M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 93,500
Avg Vol 145,892
Day's Range N/A - N/A
Shares Out 14.68M
Stochastic %K 16%
Beta 1.40
Analysts Strong Sell
Price Target $47.50

Company Profile

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Phase IIb and 3 Phase I clinical trial designed to evaluate the safety and efficacy of GLSI-100 in HER2...

Industry: Biotechnology
Sector: Healthcare
Phone: 832-819-3232
Address:
Building 14, 3992 Bluebonnet Dr., Stafford, United States
manuel077
manuel077 Jul. 14 at 5:35 PM
$GLSI Is there any bear here? Or anyone shorting the stock long-term? Would be reall nice to have discussion why you think Glsi will fail...
2 · Reply
Rolltide2020
Rolltide2020 Jul. 14 at 4:05 PM
$GLSI My honest opinion right now (and I'm still bullish and will Thelma and Louise this right over the cliff) is that they are considering to change the trial / interim analyis to account for the possibility of early recurrences due to peak immunity not occuring until 6 months. This is a legitimate request and they should still be able to get this done if it occurs before unblinding. Snehal seemed to indicate this in the last video (around the 14 minute mark) where the non-HLA effect was possibly greater than 50% and closer to 70% to 80% after the first 6 months. I don't think they will need this change in order to meet targeted results, but why leave it to chance if the peak effect takes 6 months.
1 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Jul. 14 at 3:15 PM
$GLSI new look on Fintel
3 · Reply
ROFLMAOO
ROFLMAOO Jul. 14 at 2:20 PM
$GLSI gonna have to extend the lock up or not sure why snehal was buying $27
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Jul. 14 at 1:52 PM
$GLSI mental "gymnastics"
2 · Reply
White_valkyrie0
White_valkyrie0 Jul. 14 at 12:59 PM
$GLSI if we were in a 3 vs 11 or 4 vs 10 we already have hit the interim just do the math with the 900 patients till december 2025 3 cohorts multiply by 0.29% and the months till july 2026
0 · Reply
White_valkyrie0
White_valkyrie0 Jul. 14 at 12:47 PM
$GLSI many of you are extremelly conservative and i get why. this is not your first time investing in pharma maybe, but it did not go well the other times right? you can tell by the way you are doing constant mental gymnastics on irrelevant things. i am sorry if you lost money before and want to be conservative by saying just a 100$ share and the interim will happen in 2034, i get it but bro, this is not difficult to calculate
0 · Reply
White_valkyrie0
White_valkyrie0 Jul. 14 at 12:43 PM
$GLSI if we don’t stop by interim for superiority, be aware we will have to wait till year end 2027 to get 28 total. do your math with your money and if you are able to wait 1 year and a half of share price falling good for you the interim will hit before september ends mark this, with 14 events, if the changed it, they have to disclose it
0 · Reply
Rolltide2020
Rolltide2020 Jul. 14 at 12:35 PM
$GLSI Is it just me, or does WV seem pressed?
2 · Reply
White_valkyrie0
White_valkyrie0 Jul. 14 at 12:32 PM
$GLSI there were 1000 screened at 3th december 2025 thats like at least 900 enrrolled 7 months ago bro i mean do you read the news?
1 · Reply
Latest News on GLSI
Greenwich LifeSciences Quarterly report: Q1 2026

Jun 4, 2026, 8:00 AM EDT - 5 weeks ago

Greenwich LifeSciences Quarterly report: Q1 2026


Greenwich LifeSciences presents FLAMINGO-01 data at ASCO

2026-06-01T14:32:25.000Z - 6 weeks ago

Greenwich LifeSciences presents FLAMINGO-01 data at ASCO


Greenwich LifeSciences Annual report: Q4 2025

Jun 1, 2026, 8:00 AM EDT - 6 weeks ago

Greenwich LifeSciences Annual report: Q4 2025


Greenwich LifeSciences provides update on 10-K filing

2026-06-01T10:21:46.000Z - 6 weeks ago

Greenwich LifeSciences provides update on 10-K filing


Greenwich LifeSciences says Form 10-K ‘still being audited’

2026-04-30T10:11:17.000Z - 2 months ago

Greenwich LifeSciences says Form 10-K ‘still being audited’


Greenwich LifeSciences Provides Update on Financing Strategy

Apr 14, 2026, 6:00 AM EDT - 3 months ago

Greenwich LifeSciences Provides Update on Financing Strategy


Greenwich LifeSciences adds City of Hope to FLAMINGO-01 trial

2026-03-19T10:12:27.000Z - 4 months ago

Greenwich LifeSciences adds City of Hope to FLAMINGO-01 trial


Greenwich LifeSciences Provides Update on Upcoming AACR Meeting

Mar 18, 2026, 6:00 AM EDT - 4 months ago

Greenwich LifeSciences Provides Update on Upcoming AACR Meeting


Greenwich LifeSciences Transcript: Noble Conference

Dec 3, 2025, 7:00 AM EST - 7 months ago

Greenwich LifeSciences Transcript: Noble Conference


Greenwich LifeSciences Quarterly report: Q3 2025

Nov 14, 2025, 7:00 AM EST - 8 months ago

Greenwich LifeSciences Quarterly report: Q3 2025


Greenwich LifeSciences Proxy statement: Proxy filing

Nov 3, 2025, 7:00 AM EST - 9 months ago

Greenwich LifeSciences Proxy statement: Proxy filing


Greenwich LifeSciences Proxy statement: Proxy filing

Nov 3, 2025, 7:00 AM EST - 9 months ago

Greenwich LifeSciences Proxy statement: Proxy filing


Greenwich LifeSciences Quarterly report: Q2 2025

Aug 14, 2025, 8:00 AM EDT - 11 months ago

Greenwich LifeSciences Quarterly report: Q2 2025


Greenwich LifeSciences Slides: Corporate presentation

Jun 15, 2025, 7:00 AM EDT - 1 year ago

Greenwich LifeSciences Slides: Corporate presentation


Greenwich LifeSciences Quarterly report: Q1 2025

May 20, 2025, 8:00 AM EDT - 1 year ago

Greenwich LifeSciences Quarterly report: Q1 2025


Greenwich LifeSciences Annual report: Q4 2024

Apr 15, 2025, 8:00 AM EDT - 1 year ago

Greenwich LifeSciences Annual report: Q4 2024


Greenwich LifeSciences Provides Global Update on FLAMINGO-01

Apr 3, 2025, 8:00 AM EDT - 1 year ago

Greenwich LifeSciences Provides Global Update on FLAMINGO-01


Greenwich LifeSciences Partners with GIM in Italy

Nov 26, 2024, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Partners with GIM in Italy


Greenwich LifeSciences Provides Update on Corporate Events

Nov 18, 2024, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Provides Update on Corporate Events


Greenwich LifeSciences Quarterly report: Q3 2024

Nov 14, 2024, 7:00 AM EST - 1 year ago

Greenwich LifeSciences Quarterly report: Q3 2024


Greenwich LifeSciences Proxy statement: Proxy filing

Nov 1, 2024, 8:00 AM EDT - 1 year ago

Greenwich LifeSciences Proxy statement: Proxy filing


Greenwich LifeSciences Proxy statement: Proxy filing

Nov 1, 2024, 8:00 AM EDT - 1 year ago

Greenwich LifeSciences Proxy statement: Proxy filing


Greenwich LifeSciences Quarterly report: Q2 2024

Aug 14, 2024, 8:00 AM EDT - 2 years ago

Greenwich LifeSciences Quarterly report: Q2 2024


Greenwich LifeSciences Set to Join Russell 2000 Index Again

Jun 26, 2024, 7:33 AM EDT - 2 years ago

Greenwich LifeSciences Set to Join Russell 2000 Index Again


Greenwich LifeSciences Announces $2.5 Million Private Placement

Jun 14, 2024, 6:00 AM EDT - 2 years ago

Greenwich LifeSciences Announces $2.5 Million Private Placement


Greenwich LifeSciences Transcript: Virtual Equity Conference

Jun 4, 2024, 7:00 AM EDT - 2 years ago

Greenwich LifeSciences Transcript: Virtual Equity Conference


Greenwich LifeSciences Quarterly report: Q1 2024

May 20, 2024, 8:00 AM EDT - 2 years ago

Greenwich LifeSciences Quarterly report: Q1 2024


Greenwich LifeSciences Annual report: Q4 2023

Apr 15, 2024, 8:00 AM EDT - 2 years ago

Greenwich LifeSciences Annual report: Q4 2023


manuel077
manuel077 Jul. 14 at 5:35 PM
$GLSI Is there any bear here? Or anyone shorting the stock long-term? Would be reall nice to have discussion why you think Glsi will fail...
2 · Reply
Rolltide2020
Rolltide2020 Jul. 14 at 4:05 PM
$GLSI My honest opinion right now (and I'm still bullish and will Thelma and Louise this right over the cliff) is that they are considering to change the trial / interim analyis to account for the possibility of early recurrences due to peak immunity not occuring until 6 months. This is a legitimate request and they should still be able to get this done if it occurs before unblinding. Snehal seemed to indicate this in the last video (around the 14 minute mark) where the non-HLA effect was possibly greater than 50% and closer to 70% to 80% after the first 6 months. I don't think they will need this change in order to meet targeted results, but why leave it to chance if the peak effect takes 6 months.
1 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Jul. 14 at 3:15 PM
$GLSI new look on Fintel
3 · Reply
ROFLMAOO
ROFLMAOO Jul. 14 at 2:20 PM
$GLSI gonna have to extend the lock up or not sure why snehal was buying $27
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Jul. 14 at 1:52 PM
$GLSI mental "gymnastics"
2 · Reply
White_valkyrie0
White_valkyrie0 Jul. 14 at 12:59 PM
$GLSI if we were in a 3 vs 11 or 4 vs 10 we already have hit the interim just do the math with the 900 patients till december 2025 3 cohorts multiply by 0.29% and the months till july 2026
0 · Reply
White_valkyrie0
White_valkyrie0 Jul. 14 at 12:47 PM
$GLSI many of you are extremelly conservative and i get why. this is not your first time investing in pharma maybe, but it did not go well the other times right? you can tell by the way you are doing constant mental gymnastics on irrelevant things. i am sorry if you lost money before and want to be conservative by saying just a 100$ share and the interim will happen in 2034, i get it but bro, this is not difficult to calculate
0 · Reply
White_valkyrie0
White_valkyrie0 Jul. 14 at 12:43 PM
$GLSI if we don’t stop by interim for superiority, be aware we will have to wait till year end 2027 to get 28 total. do your math with your money and if you are able to wait 1 year and a half of share price falling good for you the interim will hit before september ends mark this, with 14 events, if the changed it, they have to disclose it
0 · Reply
Rolltide2020
Rolltide2020 Jul. 14 at 12:35 PM
$GLSI Is it just me, or does WV seem pressed?
2 · Reply
White_valkyrie0
White_valkyrie0 Jul. 14 at 12:32 PM
$GLSI there were 1000 screened at 3th december 2025 thats like at least 900 enrrolled 7 months ago bro i mean do you read the news?
1 · Reply
White_valkyrie0
White_valkyrie0 Jul. 14 at 12:30 PM
$GLSI replace what? bro ajajajaja i mean really? did you read the prospect of this vaccine? did you know it works after kadcyla ? replace what bro? it seems as is said you don’t really know in what you are investing
0 · Reply
White_valkyrie0
White_valkyrie0 Jul. 14 at 3:01 AM
$GLSI is this simple, if futility means stop the trial because the vaccine does not work… then, what is the meaning of superiority at 14 events? go ahead, i think you can get the answer. we get a 1 vs 13 scenario and the trial goes till 28 events right? now i get why most of the people on stocktwits are just or bagholders or retail without a clue in what they are investing
4 · Reply
White_valkyrie0
White_valkyrie0 Jul. 14 at 2:51 AM
$GLSI the trial can be stopped due superiority on a 1 vs 13 scenario. this is not some random afirmation, its the way this trials work bro. do your DD and ask AI about this, if the trial cant be stopped them why is there an interim? for safety reason, right? no jaajajaja read the flamingo 01 prospect and read well
1 · Reply
White_valkyrie0
White_valkyrie0 Jul. 14 at 2:49 AM
$GLSI the interim will be done at 14 events, not because for a safety reason, but because futility or efficacy bro. stop with this, the trial can be halted if there is a 1 vs 13 difference. did you ask the proper questions? did you do your own DD? did you winter why this trial is only 250 patients per group and not 750 per group like others? bro is just simple, ask AI
0 · Reply
Rolltide2020
Rolltide2020 Jul. 13 at 11:50 PM
$GLSI Interesting to listen to this again 5 weeks later.…..especially from 36:25 to end. No need to guess what is going to happen next, just listen to Snehal, he is telling you what’s next. https://youtu.be/kirV0jXXjoI?is=AUXMx7OoueGmfQMC
1 · Reply
TheinvestmetABCD
TheinvestmetABCD Jul. 13 at 11:08 PM
$GLSI time is on our side, the longer it takes for the interim analysis the more conviction Investors will have that the drug is working even if DSMB says just trial „continue“. This continuation is what many institutions are waiting for to get in slowly. Potential partners/buyers also want to wait for this signal before they strike a deal. It is the Most derisking event for them. SLS share price also started to climb after their interim anslysis and it will happen here if trial continues. Also the more patients get enrolled into the trial before interim, the higher the chances the trial gets stopped early due to overwhelming efficacy. I would not say 0 chance for that. Many people believe they have time here, but one partnership news with upfront cash payment and we will trade at $60-80 easily. One of the strongest arguments for bears is the low cash position and usage of ATM, if we solve this one plus no futility, the stock will start to rerate aggressively. Until then chill
0 · Reply
Rolltide2020
Rolltide2020 Jul. 13 at 9:09 PM
$GLSI Interesting (from Chat). I assumed we would find out event split count at Interim Analysis, but it sounds like that will not happen unless stopped for efficacy or inferiority. Guess we just need to be stopped for efficacy. 🤷‍♂️ For FLAMINGO-01 Based on what has been publicly described, the most likely possibilities are: If the DSMB says "continue as planned," GLSI remains blinded and does not receive the event split. If the DSMB recommends stopping for efficacy, futility, or safety, GLSI would receive enough unblinded information to act on that recommendation. So, while it is theoretically possible for a sponsor to request unblinding, it would be unusual for regulators, the DSMB, or the trial's governance structure to allow disclosure of the treatment-group event counts simply because the company wanted to know. The integrity of the trial depends on maintaining the blind unless there is a compelling, pre-specified reason to break it.
1 · Reply
White_valkyrie0
White_valkyrie0 Jul. 13 at 9:05 PM
$GLSI i almost forgot about the interim. if we get a 1 vs 13 or even 2 vs 12 events (which is where we are heading) the trial on hla02 types will be stopped due to overwhelming efficacy. this is not some farytail, or farydust invention ask, gemini, chat gpt, or whatever AI, it will all tell you the same scenario.
1 · Reply
White_valkyrie0
White_valkyrie0 Jul. 13 at 7:17 PM
$GLSI $GLSI with approval 100$ a share? 1,5 billion market cap? idk bro jaajajajaja that seems very unfair for a product that can genérate 4+billion$ a year for the next 10 years…. idk maybe i am to optimistc xd but if you sell at 100$ and this goes to 750$, don’t blame anybody
2 · Reply
Rolltide2020
Rolltide2020 Jul. 13 at 5:36 PM
$GLSI The video isn't new, but the LinkedIn post is new.
1 · Reply
doc123266
doc123266 Jul. 13 at 5:17 PM
$GLSI I definitely didn’t intend to diminish all of the amazing aspects of this company. Was just saying the lockup isn’t that important to me.
1 · Reply
Rolltide2020
Rolltide2020 Jul. 13 at 5:12 PM
$GLSI If we get approval, we go over $100/share (possibly much higher). If we don't get approval, we go to $0. If you are holding for end game like me, I guess it doesn't really matter if you go to $0 or $100+ from $18 or $30. All of us speculating right now, which is fun and helps pass the time while we wait (and maybe helps us with our future investments). I guess it is always nice to be closer to $30 in case you have to sell unexpectantly, but let's be honest.....this was never going to be a linear move.
0 · Reply